Pancreatic Cancer Research

ResearcherUniversity of LondonActive in the last 2 years

Jun Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2509-9599; OpenAlex author ID A5100686100. Sources: OpenAlex.

Their work

Papers
10 (first author 2, last author 2)
Trials
0
Grants
0
Labs led
0
Collaborators
31
Papers, trials and grants by year

2013: 1 paper · 2014: 1 paper · 2015: none · 2016: 2 papers · 2017: 1 paper · 2018: none · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: 2 papers · 2024: none · 2025: none · 2026: 1 paper

Papers 10

  1. Matrix stiffness shapes transcriptional profiles and drug responses of pancreatic cancer cells. Co-author DOI 10.1016/j.actbio.2025.12.020↗
  2. Non-coding mutations at enhancer clusters contribute to pancreatic ductal adenocarcinoma Last author DOI 10.1101/2023.06.28.546873↗
  3. Non-coding mutations at enhancer clusters contribute to pancreatic ductal adenocarcinoma Co-author DOI 10.21203/rs.3.rs-3120592/v1↗
  4. Correction: A Virus-infected, Reprogrammed Somatic Cell-derived Tumor Cell (VIReST) Vaccination Regime can Prevent Initiation and Progression of Pancreatic Can… Co-author DOI 10.1158/1078-0432.ccr-21-0850↗
  5. A Virus-Infected, Reprogrammed Somatic Cell-Derived Tumor Cell (VIReST) Vaccination Regime Can Prevent Initiation and Progression of Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-19-1395↗
  6. Splice variants as novel targets in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-017-03354-z↗
  7. The construction and proliferative effects of a lentiviral vector capable of stably overexpressing SPINK1 gene in human pancreatic cancer AsPC-1 cell line. Last author DOI 10.1007/s13277-015-4405-z↗
  8. Reduced Expression of Histone Methyltransferases KMT2C and KMT2D Correlates with Improved Outcome in Pancreatic Ductal Adenocarcinoma. First author DOI 10.1158/0008-5472.can-16-0481↗
  9. A multi-gene signature predicts outcome in patients with pancreatic ductal adenocarcinoma. First author DOI 10.1186/s13073-014-0105-3↗
  10. Activated pancreatic stellate cells sequester CD8+ T cells to reduce their infiltration of the juxtatumoral compartment of pancreatic ductal adenocarcinoma. Co-author DOI 10.1053/j.gastro.2013.07.025↗

Closest collaborators

The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hemant Mahendrakumar Kocher · 6 shared papers, 2013–2026 · strength 0.77
  2. Eleni Maniati · 4 shared papers, 2016–2026 · strength 0.70
  3. Claude Chelala · 6 shared papers, 2013–2021 · strength 0.36
  4. Madapura M. Pradeepa · 2 shared papers, 2023 · strength 0.35
  5. Minal B. Patel · 2 shared papers, 2023 · strength 0.35
  6. Daniela Loessner · 1 shared paper, 2026 · strength 0.29
  7. Elena Tomás Bort · 1 shared paper, 2026 · strength 0.29
  8. Rodrigo Curvello · 1 shared paper, 2026 · strength 0.29
  9. Shreya Sharma · 1 shared paper, 2026 · strength 0.29
  10. Eleonora Peerani · 1 shared paper, 2026 · strength 0.29
  11. Juliana B. Candido · 1 shared paper, 2026 · strength 0.29
  12. Shuangshuang Lu · 2 shared papers, 2020–2021 · strength 0.17
  13. Louisa S. Chard Dunmall · 2 shared papers, 2020–2021 · strength 0.17
  14. Yaohe Wang · 2 shared papers, 2020–2021 · strength 0.17
  15. Laurent Dumartin · 2 shared papers, 2014–2017 · strength 0.10
  16. Tatjana Crnogorac‐Jurcevic · 2 shared papers, 2014–2017 · strength 0.10
  17. Aldo Scarpa Scarpa · 2 shared papers, 2014–2017 · strength 0.10
  18. Zhe Zhang · 1 shared paper, 2021 · strength 0.09
  19. Jing Zhang · 1 shared paper, 2016 · strength 0.07
  20. John F. Marshall · 2 shared papers, 2013–2014 · strength 0.07
  21. Tomasz P. Radon · 1 shared paper, 2017 · strength 0.06
  22. Andrea Mafficini · 1 shared paper, 2017 · strength 0.06
  23. Rita Teresa Lawlor · 1 shared paper, 2017 · strength 0.06
  24. Roberto Salvia · 1 shared paper, 2017 · strength 0.06
  25. Joshua B.N. Dawkins · 1 shared paper, 2016 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.